On July 28, Repligen surged 15.35% in regular trading, trading at $149.24/share, with turnover of $99.10 million. The rally was driven by the company's Q2 earnings report released before market open, which significantly exceeded Wall Street expectations on all metrics.

Repligen reported Q2 adjusted earnings of $0.54 per diluted share, beating the analyst consensus estimate of $0.45 by 20% and representing a 45.95% increase from $0.37 in the year-ago quarter. Revenue came in at $204.1 million, surpassing the expected $201.6 million, up 11.9% year-over-year. The company also raised its full-year outlook, now expecting adjusted EPS of $2.03 to $2.09, up from the prior range of $1.97 to $2.05, compared to the FactSet consensus of $2.00. Revenue guidance was lifted to $813 million to $835 million from $803 million to $833 million previously.

Repligen is a global life sciences company headquartered in Waltham, Massachusetts, developing and commercializing bioprocessing equipment and consumables used in the manufacture of biological drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)